Nurix therapeutics announces presentation of preclinical data from nx-5948 program demonstrating significant reduction of inflammation in a model of autoimmune disease

Orally available nx-5948 is a potent selective degrader of bruton's tyrosine kinase (btk) without imid activity

NRIX Ratings Summary

NRIX Quant Ranking